ArticleJournal of thoracic diseasePublished
Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
Regional connection
Verified An author affiliation on the Europe PMC record names Hospital of the University of Pennsylvania, with Penn Medicine linked by the institution reference. Affiliation source
- Institutions
- Hospital of the University of Pennsylvania, Penn Medicine
- County
- Philadelphia County
Publication record
- Type
- Article
- Venue
- Journal of thoracic disease
- Published
- Topic
- Clinical care
- Subject terms
- Non-small cell lung cancer (NSCLC); Afatinib; Epidermal Growth Factor Receptor Mutations (Egfr Mutations); Osimertinib; Egfr Tyrosine Kinase Inhibitor (Egfr Tki)
- PubMed ID
- 38090314
- PubMed Central ID
- PMC10713299
- Open access
- Yes, open
- Added to directory
- Source checked